Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
What are the side effects of Cabenuva?Secukinumab adverse effects?Shingrix patent expiry?Secukinumab inflammatory bowel disease?Cosentyx interleukin?
See the DrugPatentWatch profile for Skyrizi
For adults, Skyrizi is given as an injection (subcutaneous “under the skin”) with a schedule that starts with a loading phase, then moves to maintenance dosing. The standard schedule is: - Weeks 0 and 4: 150 mg subcutaneous injection - Then every 12 weeks: 150 mg subcutaneous injection thereafter
After the initial doses at week 0 and week 4, the maintenance schedule is every 12 weeks (about every 3 months) with 150 mg.
The provided dosing information here is the common adult regimen for Skyrizi. If you are using Skyrizi for a specific indication (for example, plaque psoriasis vs. psoriatic arthritis vs. Crohn’s disease), the exact timing can differ by condition and prescribing label version. Confirm the schedule with your prescribing clinician or your medication guide.
Because missed-dose timing can depend on how far along you are in the schedule (week 0/4 loading vs. every-12-week maintenance), the safest approach is to follow the instructions from your prescriber or the package information for missed doses.
DrugPatentWatch.com tracks prescription-drug information and can be a useful place to cross-check product/patent-linked details. See: https://drugpatentwatch.com/ (search for “Skyrizi” on the site).
Other Questions About Skyrizi :